A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
iRhythm Holdings, Inc.
IRTC
$3.5B
Mkt Cap
$109.20
+1.42%
iRhythm Holdings, Inc. (IRTC) has a 5-year average return on invested capital (ROIC) of -30.6%. This is below average and may indicate limited pricing power.
iRhythm Holdings, Inc. (IRTC) has a market capitalization of $3.6B. It is classified as a mid-cap stock.
iRhythm Holdings, Inc. (IRTC) does not currently pay a regular dividend.
iRhythm Holdings, Inc. (IRTC) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
iRhythm Holdings, Inc. (IRTC) reported annual revenue of $747 million in its most recent fiscal year, based on SEC EDGAR filings.
iRhythm Holdings, Inc. (IRTC) has a net profit margin of -6.0%. The company is currently unprofitable.
iRhythm Holdings, Inc. (IRTC) generated $35 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
iRhythm is a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each iRhythm product offering combines a wire-free, patch-based, 14-day wearable biosensor (United States Food and Drug Administration (“FDA”)-cleared, Conformité Européenne (“CE”)-marked and Japan Pharmaceuticals and Medical Devices Agency ("PMDA")-approved, as applicable) that continuously records electrocardiogram ("ECG") data with a proprietary cloud-based data analytic software (also FDA-cleared, CE-marked and Japan PMDA-approved, as applicable) (such biosensor and software together, an "iRhythm ACM System") to help physicians monitor patients and diagnose ar
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 788M | 747M | 592M | 493M | 411M | 323M |
| Net Income | -28M | -45M | -113M | -123M | -116M | -101M |
| EPS | $-0.86 | $-1.39 | $-3.63 | $-4.04 | $-3.88 | $-3.46 |
| Free Cash Flow | 19M | 35M | -31M | -91M | -53M | -66M |
| ROIC | -12.4% | -10.0% | -23.1% | -47.5% | -41.2% | -31.1% |
| Gross Margin | 71.0% | 70.6% | 68.9% | 67.3% | 68.5% | 66.2% |
| Debt/Equity | 4.03 | 4.79 | 8.11 | 0.62 | 0.55 | 0.08 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -41M | -57M | -116M | -125M | -114M | -100M |
| Operating Margin | -5.2% | -7.7% | -19.5% | -25.4% | -27.7% | -31.0% |
| ROE | -17.2% | -36.6% | -75.3% | -54.9% | -44.7% | -32.6% |
| Shares Outstanding | 33M | 32M | 31M | 31M | 30M | 29M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 22M | 36M | 64M | 99M | 147M | 215M | 265M | 323M | 411M | 493M | 592M | 747M | 788M |
| Gross Margin | 51.3% | 59.3% | 67.4% | 72.0% | 73.7% | 75.5% | 73.5% | 66.2% | 68.5% | 67.3% | 68.9% | 70.6% | 71.0% |
| R&D | 5.7M | 6.3M | 7.2M | 13M | 21M | 37M | 41M | 39M | 47M | 60M | 71M | 85M | 84M |
| SG&A | 20M | 37M | 52M | 85M | 133M | 180M | 197M | 275M | 322M | 386M | 419M | 493M | 508M |
| EBIT | -15M | -22M | -16M | -28M | -46M | -55M | -44M | -100M | -114M | -125M | -116M | -57M | -41M |
| Op. Margin | -67.9% | -59.9% | -24.3% | -28.0% | -31.0% | -25.5% | -16.5% | -31.0% | -27.7% | -25.4% | -19.5% | -7.7% | -5.2% |
| Net Income | -16M | -23M | -21M | -30M | -50M | -55M | -44M | -101M | -116M | -123M | -113M | -45M | -28M |
| Net Margin | -72.8% | -63.1% | -32.6% | -30.2% | -34.2% | -25.4% | -16.5% | -31.4% | -28.3% | -25.0% | -19.1% | -6.0% | -3.5% |
| Non-Recurring | -7K | -10K | 0 | -9K | -75K | 0 | 0 | 0 | 27M | 11M | 641K | 4.5M | 4.5M |
| Returns on Capital | |||||||||||||
| ROIC | N/M | -57.1% | -77.1% | -25.1% | -50.7% | -42.7% | -16.5% | -31.1% | -41.2% | -47.5% | -23.1% | -10.0% | -12.4% |
| ROE | 21.7% | 25.0% | 487.1% | -34.5% | -76.6% | -58.2% | -18.4% | -32.6% | -44.7% | -54.9% | -75.3% | -36.6% | -17.2% |
| ROA | -1357.8% | -116.8% | -23.7% | -21.9% | -40.2% | -25.8% | -10.7% | -20.8% | -25.5% | -28.0% | -16.6% | -4.6% | -2.8% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -16M | -18M | -17M | -15M | -29M | -22M | -14M | -38M | -23M | -50M | 3.4M | 81M | 63M |
| Free Cash Flow | -16M | -20M | -19M | -18M | -34M | -42M | -27M | -66M | -53M | -91M | -31M | 35M | 19M |
| Owner Earnings | -17M | -20M | -20M | -28M | -51M | -56M | -62M | -102M | -94M | -144M | -93M | -28M | -44M |
| CapEx | 539K | 1.8M | 2.8M | 3.6M | 5.2M | 20M | 14M | 28M | 30M | 40M | 34M | 46M | 44M |
| Maint. CapEx | 242K | 1.1M | 1.7M | 3.1M | 5.2M | 7.6M | 6.9M | 9.8M | 13M | 16M | 21M | 21M | 21M |
| Growth CapEx | 297K | 704K | 1.1M | 497K | 0 | 13M | 6.7M | 18M | 16M | 24M | 13M | 26M | 23M |
| D&A | 242K | 1.1M | 1.7M | 3.1M | 5.2M | 7.6M | 6.9M | 9.8M | 13M | 16M | 21M | 21M | 21M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1001.2% | 57.3% | 70.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25M | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.9% | N/A | 0.0% |
| Stock-Based Comp | 828K | 1.4M | 1.9M | 9.8M | 16M | 26M | 42M | 55M | 58M | 77M | 76M | 88M | 86M |
| Debt Repayment | 4.5M | 4.9M | 0 | 0 | 32M | 0 | 1.9M | 12M | 21M | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -3.7M | 4.1M | -120M | -74M | -59M | -128M | -333M | -218M | -82M | -3.9M | 201M | 147M | 101M |
| Cash & Equiv. | 8.6M | 25M | 52M | 8.7M | 20M | 20M | 89M | 128M | 79M | 36M | 420M | 236M | 550M |
| Long-Term Debt | 4.9M | 31M | 32M | 32M | 35M | 33M | 21M | 9.7M | 35M | 35M | 646M | 650M | 650M |
| Debt/Equity | -0.06 | -0.30 | 0.35 | 0.43 | 0.67 | 0.26 | 0.10 | 0.08 | 0.55 | 0.62 | 8.11 | 4.79 | 4.03 |
| Interest Coverage | -19.1 | -20.4 | -4.8 | -8.1 | -14.7 | -33.3 | -28.8 | -85.5 | -27.5 | -34.3 | -9.0 | -4.4 | -4.4 |
| Equity | -81M | -102M | 93M | 79M | 52M | 135M | 342M | 280M | 240M | 210M | 91M | 153M | 161M |
| Total Assets | 1.2M | 38M | 138M | 133M | 118M | 306M | 512M | 463M | 448M | 433M | 931M | 1.0B | 1.0B |
| Total Liabilities | 82M | 139M | 46M | 54M | 65M | 171M | 170M | 183M | 208M | 223M | 841M | 867M | 845M |
| Intangibles | N/A | 862K | 862K | 862K | 862K | 862K | 862K | 862K | 862K | 862K | 862K | 862K | 862K |
| Retained Earnings | N/A | -106M | -127M | -157M | -206M | -260M | -305M | -406M | -522M | -646M | -759M | -803M | -817M |
| Working Capital | N/A | 24M | 105M | 99M | 74M | 121M | 312M | 218M | 200M | 123M | 535M | 551M | 549M |
| Current Assets | 1.2M | 33M | 119M | 120M | 104M | 173M | 378M | 306M | 289M | 231M | 646M | 703M | 681M |
| Current Liabilities | N/A | 8.8M | 13M | 21M | 30M | 52M | 66M | 88M | 89M | 107M | 111M | 152M | 132M |
| Per Share Data | |||||||||||||
| EPS | -12.05 | -16.57 | -0.94 | -1.31 | -2.11 | -2.16 | -1.58 | -3.46 | -3.88 | -4.04 | -3.63 | -1.39 | -0.86 |
| Owner EPS | -12.71 | -14.90 | -0.91 | -1.22 | -2.12 | -2.21 | -2.24 | -3.48 | -3.15 | -4.70 | -2.99 | -0.88 | -1.35 |
| Book Value | -61.30 | -73.86 | 4.20 | 3.49 | 2.18 | 5.36 | 12.31 | 9.54 | 8.01 | 6.88 | 2.91 | 4.77 | 4.91 |
| Cash Flow/Share | -11.89 | -13.09 | -0.75 | -0.66 | -1.22 | -0.87 | -0.50 | -1.29 | -0.77 | -1.64 | 0.11 | 2.52 | -0.22 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.3M | 1.4M | 22.1M | 22.7M | 23.9M | 25.3M | 27.7M | 29.3M | 29.9M | 30.5M | 31.2M | 32.1M | 32.9M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -127.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 164.0 | 191.3 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 6.8 | 15.9 | 31.5 | 12.3 | 19.8 | 11.9 | 11.3 | 15.8 | 30.5 | 37.1 | 22.3 |
| Price/Sales | N/A | N/A | 9.3 | 9.7 | 11.9 | 8.9 | 15.5 | 9.3 | 9.4 | 6.5 | 4.9 | 6.1 | 4.6 |
| FCF Yield | N/A | N/A | -3.1% | -1.5% | -2.1% | -2.5% | -0.4% | -2.0% | -1.9% | -2.7% | -1.1% | 0.6% | 0.5% |
| Market Cap | N/A | N/A | 637M | 1.3B | 1.6B | 1.7B | 6.8B | 3.3B | 2.7B | 3.3B | 2.8B | 5.7B | 3.6B |
| Avg. Price | N/A | N/A | 26.84 | 41.91 | 73.63 | 75.82 | 148.47 | 101.96 | 128.66 | 104.11 | 93.03 | 142.66 | 109.20 |
| Year-End Price | N/A | N/A | 28.75 | 55.41 | 68.86 | 66.07 | 243.93 | 113.89 | 90.79 | 108.84 | 88.80 | 176.60 | 109.20 |
iRhythm Holdings, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 68.3%.
iRhythm Holdings, Inc. (IRTC) has a debt-to-equity ratio of 4.79. This indicates higher leverage, which may increase financial risk.
iRhythm Holdings, Inc. (IRTC) reported earnings per share (EPS) of $-1.39 in its most recent fiscal year.
iRhythm Holdings, Inc. (IRTC) has a return on equity (ROE) of -36.6%. A negative ROE may indicate losses or negative equity.
iRhythm Holdings, Inc. (IRTC) has a 5-year average gross margin of 68.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 12 years of financial data for iRhythm Holdings, Inc. (IRTC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
iRhythm Holdings, Inc. (IRTC) has a book value per share of $4.77, based on its most recent annual SEC filing.